These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 23757746)

  • 41. The rosiglitazone decision process at FDA and EMA. What should we learn?
    Pouwels KB; van Grootheest K
    Int J Risk Saf Med; 2012; 24(2):73-80. PubMed ID: 22751189
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Incidence rates of heart failure, stroke, and acute myocardial infarction among Type 2 diabetic patients using insulin glargine and other insulin.
    Juhaeri J; Gao S; Dai WS
    Pharmacoepidemiol Drug Saf; 2009 Jun; 18(6):497-503. PubMed ID: 19326365
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Insulin glargine in children aged 2 to 5 years.
    Prescrire Int; 2013 Mar; 22(136):69. PubMed ID: 23593690
    [TBL] [Abstract][Full Text] [Related]  

  • 44. An analysis of the impact of FDA's guidelines for addressing cardiovascular risk of drugs for type 2 diabetes on clinical development.
    Viereck C; Boudes P
    Contemp Clin Trials; 2011 May; 32(3):324-32. PubMed ID: 21266202
    [TBL] [Abstract][Full Text] [Related]  

  • 45. European drug agency extends review of safety of pioglitazone.
    Moynihan R
    BMJ; 2011 Jun; 342():d4105. PubMed ID: 21715461
    [No Abstract]   [Full Text] [Related]  

  • 46. Response to Hitman. Insulin degludec: a new insulin for today?
    Schmidt TA
    Diabet Med; 2014 Mar; 31(3):377-8. PubMed ID: 24354502
    [No Abstract]   [Full Text] [Related]  

  • 47. Licensing drugs for diabetes.
    Lehman R; Yudkin JS; Krumholz H
    BMJ; 2010 Sep; 341():c4805. PubMed ID: 20819887
    [No Abstract]   [Full Text] [Related]  

  • 48. After Avandia, some seek split in drug approval and monitoring.
    Dolgin E
    Nat Med; 2010 Aug; 16(8):831. PubMed ID: 20689527
    [No Abstract]   [Full Text] [Related]  

  • 49. Observational studies of drug safety--aprotinin and the absence of transparency.
    Hiatt WR
    N Engl J Med; 2006 Nov; 355(21):2171-3. PubMed ID: 17124013
    [No Abstract]   [Full Text] [Related]  

  • 50. Cardiovascular risk of oral antidiabetic drugs: current evidence and regulatory requirements for new drugs.
    Panicker GK; Karnad DR; Salvi V; Kothari S
    J Assoc Physicians India; 2012 Jan; 60():56-61. PubMed ID: 22715547
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Novel diabetes drugs to face higher hurdles?
    Opar A
    Nat Rev Drug Discov; 2007 Sep; 6(9):687-9. PubMed ID: 17907340
    [No Abstract]   [Full Text] [Related]  

  • 52. Rosiglitazone: failure of oversight or demons imagined?
    Susman J
    J Fam Pract; 2007 Sep; 56(9):696, 703. PubMed ID: 17764640
    [No Abstract]   [Full Text] [Related]  

  • 53. [New evaluation by the EU approval committee. Benefits of cox-2 inhibitors outweigh possible risks (interview by Dr. Thomas Meissner)].
    Brune K
    MMW Fortschr Med; 2004 Feb; 146(9):47. PubMed ID: 15352709
    [No Abstract]   [Full Text] [Related]  

  • 54. Hypersensitivity reaction to a biosimilar insulin glargine.
    García-Nares H; Leyva-Carmona MI; Pérez-Xochipa N; Chiquete E
    J Diabetes; 2015 Mar; 7(2):155-7. PubMed ID: 25350350
    [No Abstract]   [Full Text] [Related]  

  • 55. Drugs and diabetes: understanding the new breed of cardiovascular safety trials.
    Adler AI
    Lancet Diabetes Endocrinol; 2013 Nov; 1(3):175-7. PubMed ID: 24622361
    [No Abstract]   [Full Text] [Related]  

  • 56. Insulin detemir: new drug. A second long-acting insulin analogue: many uncertainties, few advantages.
    Prescrire Int; 2006 Oct; 15(85):163-7. PubMed ID: 17121210
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Considerations for design and data analysis of noninferiority/superiority cardiovascular trials.
    Quan H; Li M; Zhao PL; Cho M; Zhang J; Wu Y
    J Biopharm Stat; 2013; 23(1):239-60. PubMed ID: 23331234
    [TBL] [Abstract][Full Text] [Related]  

  • 58. FDA panel advises easing restrictions on rosiglitazone.
    Tucker ME
    BMJ; 2013 Jun; 346():f3769. PubMed ID: 23752055
    [No Abstract]   [Full Text] [Related]  

  • 59. Regulating medicines in Europe: the European Medicines Agency, marketing authorisation, transparency and pharmacovigilance.
    Permanand G; Mossialos E; McKee M
    Clin Med (Lond); 2006; 6(1):87-90. PubMed ID: 16521363
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Rofecoxib, Merck, and the FDA.
    Villalba L; Witter J
    N Engl J Med; 2004 Dec; 351(27):2875-8; author reply 2875-8. PubMed ID: 15625745
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.